



1642
Zhu

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Attorney Docket No.: 2508.37US02

Palm

Confirmation No.: 8494

Application No.: 09/992,665

Examiner: S. Unger

Filed: November 13, 2001

Group Art Unit: 1642

For: PROFILING TUMOR SPECIFIC MARKERS FOR THE DIAGNOSIS AND
TREATMENT OF NEOPLASTIC DISEASE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Pursuant to 37 C.F.R. § 1.56, and in addition to information disclosed in Applicants' Information Disclosure Statement filed March 28, 2002 and Supplemental Information Disclosure Statement filed December 4, 2002, the attention of the Patent and Trademark Office is hereby directed to the reference listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This information is being filed before the mailing date of a first Office Action on the merits. No certification or fee is required.

I hereby certify that some items of information contained in this Information Disclosure Statement was cited in a communication from the U.S. Patent and Trademark Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1). Thus, Applicant believes that no fee is due. A copy of the PCT Written Opinion (PCT/US01/43461) dated September 22, 2004, is also enclosed.

Respectfully submitted,



Curtis B. Herbert, Ph.D., Esq.
Registration No. 45,443


Customer No. 24113
Patterson, Thunte, Skaar & Christensen, P.A.
4800 IDS Center
80 South 8th Street
Minneapolis, Minnesota 55402-2100
Telephone: (612) 349-3008

Please grant any extension of time necessary for entry; charge any fee due to Deposit Account No. 16-0631.

CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 18, 2004
Date of Deposit



Curtis B. Herbert, Ph.D., Esq.

| | | | | |
|--|---|----------------------|------------------------|-------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | | |
| | | Application Number | 10/992,665 | |
| | | Filing Date | November 13, 2001 | |
| | | First Named Inventor | Palm | |
| | | Art Unit | 1642 | |
| | | Examiner Name | S. Ungar | |
| Sheet | 1 | 1 | Attorney Docket Number | 2508.37US02 |

NON PATENT LITERATURE DOCUMENTS

| EXAMINER INITIAL* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|----------------------|--------------------------|--|----------------|
| | | IRVINE ET AL., "Cytokine Enhancement of DNA Immunization Leads to Effective Treatment of Established Pulmonary Metastases", <u>J. of Immunol.</u> (156):1, 238-245 (1996). | |
| | | OHWADA ET AL., "DNA Vaccination against HuD Antigen Elicits Antitumor Activity in a Small-Cell Lung Cancer Murine Model", <u>Am. J. Respir. Cell Mol. Bio.</u> (21), 37-43 (1999). | |
| | | PALM ET AL., "Neuron-specific splicing of zinc finger transcription factor REST/NRSF/XBR is frequent in neuroblastomas and conserved in human, mouse and rat", <u>Molecular Brain Research</u> , (72), 30-39 (1999). | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | |
|-----------------------|--------------------|
| EXAMINER SIGNATURE | DATE CONSIDERED |
|-----------------------|--------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.